{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:32Z","timestamp":1790934392926,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[1998,11,1]],"date-time":"1998-11-01T00:00:00Z","timestamp":909878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Raloxifene is a selective estrogen receptor modulator that in experimental animals acts as an estrogen receptor antagonist in breast and endometrium but as an estrogen receptor agonist in the skeletal and cardiovascular systems. We conducted a 1-year prospective, randomized, double-blind trial in 143 postmenopausal osteoporotic women (mean \u00b1 SD age, 68.4 \u00b1 5.0 years) with at least one prevalent vertebral fractures and low bone mineral density (BMD), comparing groups receiving raloxifene at 60 mg\/day (RLX60) or 120 mg\/day (RLX120) and a control group receiving supplements of 750 mg\/day of calcium and 400 IU\/day of vitamin D. There were no differences among groups in the occurrence of uterine bleeding, thrombophlebitis, breast abnormalities, or increased endometrial thickness (assessed by ultrasonography). As compared with controls, the changes in values over 1 year for RLX60 and RLX120, respectively, were significant for serum bone alkaline phosphatase (\u221214.9%, \u22128.87%), serum osteocalcin (\u221220.7%, \u221217.0%), and urinary C-telopeptide fragment of type I collagen\/creatinine (\u221224.9%, \u221230.8%), markers of bone turnover; for serum total cholesterol (\u22127.0% for RLX60) and low density lipoprotein cholesterol (LDL) (\u221211.4% for RLX60) and for the LDL\/HDL cholesterol ratio (\u221213.2%, \u22128.3%). BMD increased significantly in the total hip (1.66% for RLX60) and ultradistal radius (2.92%, 2.50%). There were nonsignificant trends toward increases over controls in BMD for lumbar spine, total body, and total hip (for RLX120). Using a &amp;gt;15% cutoff definition, raloxifene had no effect on incident fractures, but using a &amp;gt;30% cutoff, there was a dose-related reduction (p = 0.047). We conclude that raloxifene therapy is well tolerated, reduces serum lipids, and does not stimulate the uterus or breasts. It has beneficial effects on bone, although, under the conditions of this study, these appear to be of a smaller magnitude than have been reported with estrogen therapy.<\/jats:p>","DOI":"10.1359\/jbmr.1998.13.11.1747","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T23:35:13Z","timestamp":1146094513000},"page":"1747-1754","source":"Crossref","is-referenced-by-count":181,"title":["Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial"],"prefix":"10.1093","volume":"13","author":[{"given":"Edward G.","family":"Lufkin","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Whitaker","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Mayo Clinic, Scottsdale, Arizona, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nickelsen","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Argueta","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Mayo Clinic, Scottsdale, Arizona, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Caplan","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Gundersen Clinic, La Crosse, Wisconsin, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K.","family":"Knickerbocker","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Lawrence","family":"Riggs","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020713271736200_bib1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1021\/jm00374a021","article-title":"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo[b]thien-3-yl] [4-[2-(1-piperidinyl) ethoxy]- phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity","volume":"27","author":"Jones","year":"1984","journal-title":"J Med Chem"},{"key":"2024020713271736200_bib2","first-page":"119","article-title":"Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones","volume":"10","author":"Katzenellenbogen","year":"1996","journal-title":"Mol Endocrinol"},{"key":"2024020713271736200_bib3","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.273.5279.1222","article-title":"Identification of an estrogen response element activated by metabolites of 17 \u03b2-estradiol and raloxifene","volume":"273","author":"Yang","year":"1996","journal-title":"Science"},{"key":"2024020713271736200_bib4","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"2024020713271736200_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJM199203263261308","article-title":"Tamoxifen\u2014Panacea or Pandora's box?","volume":"326","author":"Davidson","year":"1992","journal-title":"N Engl J Med"},{"key":"2024020713271736200_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0002-9343(99)80251-4","article-title":"The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women","volume":"99","author":"Grey","year":"1995","journal-title":"Am J Med"},{"key":"2024020713271736200_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1172\/JCI116985","article-title":"Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats","volume":"93","author":"Black","year":"1994","journal-title":"J Clin Invest"},{"key":"2024020713271736200_bib8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.5650110615","article-title":"A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women","volume":"11","author":"Draper","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020713271736200_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/clinchem\/30.1.56","article-title":"Simultaneous determination of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D from a single sample by dual-cartridge extraction","volume":"30","author":"Kao","year":"1984","journal-title":"Clin Chem"},{"key":"2024020713271736200_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"Riggs","year":"1990","journal-title":"N Engl J Med"},{"key":"2024020713271736200_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","author":"Lufkin","year":"1992","journal-title":"Ann Intern Med"},{"key":"2024020713271736200_bib12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"2024020713271736200_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02556210","article-title":"DEXA measurement of spine density in the lateral projection. I: Methodology","volume":"49","author":"Mazess","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2024020713271736200_bib14","first-page":"290","article-title":"Estrogen treatment of patients with established postmenopausal osteoporosis","volume":"76","author":"Lindsay","year":"1990","journal-title":"Obstet Gynecol"},{"key":"2024020713271736200_bib15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/jbmr.5650071122","article-title":"Do estrogens improve bone mineral density in osteoporotic women over age 65?","volume":"7","author":"Marx","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"Suppl","key":"2024020713271736200_bib16","doi-asserted-by":"crossref","first-page":"197S","DOI":"10.1016\/8756-3282(95)00502-1","article-title":"Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy","volume":"18","author":"Riggs","year":"1996","journal-title":"Bone"},{"key":"2024020713271736200_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0002-8703(87)90511-4","article-title":"Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study","volume":"114","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"2024020713271736200_bib18","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/01.CIR.96.6.1964","article-title":"Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits","volume":"96","author":"Bjarnason","year":"1997","journal-title":"Circulation"},{"issue":"Suppl 1","key":"2024020713271736200_bib19","first-page":"S52","article-title":"Gonadal hormone substitutes: Effects on the cardiovascular system","volume":"7","author":"Clarkson","year":"1997","journal-title":"Osteoporos Int"},{"key":"2024020713271736200_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"2024020713271736200_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jbmr.5650080714","article-title":"Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis","volume":"8","author":"Seibel","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713271736200_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-125-1-199607010-00014","article-title":"Three-year followup on effects of transdermal estrogen","volume":"125","author":"Lufkin","year":"1996","journal-title":"Ann Intern Med"},{"key":"2024020713271736200_bib23","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/0003-4819-117-12-1016","article-title":"Hormone therapy to prevent disease and prolong life in postmenopausal women","volume":"117","author":"Grady","year":"1992","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"2024020713271736200_bib24","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/0029-7844(95)00431-9","article-title":"Hormones, mood, and cognitive functioning in postmenopausal women","volume":"87","author":"Sherwin","year":"1996","journal-title":"Obstet Gynecol"},{"key":"2024020713271736200_bib25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJM199506153322401","article-title":"The use of estrogens and progestins and the risk of breast cancer in postmenopausal women","volume":"332","author":"Colditz","year":"1995","journal-title":"N Engl J Med"},{"key":"2024020713271736200_bib26","first-page":"94","article-title":"What risk hormones? Conflicting studies reveal problems in pinning down breast cancer risks","volume":"148","author":"Seachrist","year":"1995","journal-title":"Science"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1998.13.11.1747","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/13\/11\/1747\/56598790\/5650131115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/13\/11\/1747\/56598790\/5650131115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:55:57Z","timestamp":1710341757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/13\/11\/1747-1754\/7514538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11,1]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[1998,11,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1998.13.11.1747","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1998,11,1]]},"published":{"date-parts":[[1998,11,1]]}}}